1. Medtech Insight
  2. >>Policy & Regulation

Abbott’s Freestyle Libre 2 Gains Medicare Coverage

 
• By Catherine Longworth

FreeStyle Libre 2 is the only integrated continuous glucose monitoring system that continuously measures the user's blood glucose without fingersticks.

SANTA CLARA, CA/USA - JULY 29, 2017: Abbott Laboratories exterior and logo. Abbott Laboratories is an American worldwide health care company. - Image
• Source: shutterstock.com

Abbott FreeStyle Libre 2 integrated continuous glucose monitoring system will now be available to US Medicare beneficiaries with diabetes, the company announced on 1 September.

Abbott said it has now secured partial or full reimbursement for its entire FreeStyle Libre portfolio in 37 countries, including Canada, France, Germany, Japan, the UK and the US. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Commission’s Flora Giorgio Says Simplification And Safety Are Key In Evolving EU Regs

 
• By Amanda Maxwell

Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.

German Bionic Launches ‘Strongest Exoskeleton To Date’

 
• By Natasha Barrow

German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

 
• By Shubham Singh

Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.